Literature DB >> 26242341

Intraspinal Transplantation of Autologous Neurogenically-Induced Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Paraplegic Dogs without Deep Pain Perception Secondary to Intervertebral Disk Disease.

Omer Besalti1, Pinar Can, Eylul Akpinar, Zeynep Aktas, Ayse Eser Elcin, Yasar Murat Elcin.   

Abstract

AIM: To investigate the effects of neurogenically-induced autologous bone marrow-derived mesenchymal stem cells (NIBM-MSCs) in paraplegic dogs without deep pain perception (DPP) secondary to intervertebral disk disease (IVDD).
MATERIAL AND METHODS: Seven dogs which could not be improved neurologically with conventional treatment modalities were included in the study. All dogs were diagnosed by magnetic resonance imaging and surgically treated. Each dog received two times a suspension of autologous 5.0x106 NIBM-MSCs, which were positive to CNPase and MAP-2, as well as to GFAP and beta III tubulin into the spinal cord through the hemilaminectomy defect percutaneously, with a 21-day interval.
RESULTS: Two months after cell transplantation, there were no changes except for 1 gait score improvement for 1 of the cases. At the 4th month, gait score had improved 1 score in 5 cases, and one score progress was recorded in proprioception and nociception in 1 case. In eight months-followed up 4 cases were evaluated by the same parameter; gait score had improved in 3 cases, and propriception improved in 2 cases, and nociception improved in 3 cases.
CONCLUSION: Our findings suggest that utility of autologous NIBM-MSCs for cases with poor prognosis after IVDD can be a promising approach.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26242341     DOI: 10.5137/1019-5149.JTN.14502-15.2

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  7 in total

1.  Pathological changes within two weeks following spinal cord injury in a canine model.

Authors:  Yuya Nakamoto; Gentarou Tsujimoto; Akito Ikemoto; Koichi Omori; Tatsuo Nakamura
Journal:  Eur Spine J       Date:  2021-07-20       Impact factor: 3.134

2.  The use of autologous neurogenically-induced bone marrow-derived mesenchymal stem cells for the treatment of paraplegic dogs without nociception due to spinal trauma.

Authors:  Omer Besalti; Zeynep Aktas; Pinar Can; Eylul Akpinar; Ayse Eser Elcin; Yasar Murat Elcin
Journal:  J Vet Med Sci       Date:  2016-06-10       Impact factor: 1.267

Review 3.  Challenges of stem cell therapies in companion animal practice.

Authors:  Min Hee Kang; Hee Myung Park
Journal:  J Vet Sci       Date:  2020-05       Impact factor: 1.672

4.  The Long-Term Efficacy Study of Multiple Allogeneic Canine Adipose Tissue-Derived Mesenchymal Stem Cells Transplantations Combined With Surgery in Four Dogs With Lumbosacral Spinal Cord Injury.

Authors:  Chung-Chao Chen; Shu-Fang Yang; Ing-Kae Wang; Sing-Ying Hsieh; Jian-Xi Yu; Tze-Lien Wu; Wan-Jhen Huong; Min-Hao Su; Heng-Leng Yang; Pi-Chen Chang; Ann-Chi Teng; Chen Chia-Yi; Sao-Ling Liang
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

5.  Percutaneous transplantation of allogenic bone marrow-derived mesenchymal stem cells for the management of paraplegia secondary to Hansen type I intervertebral disc herniation in a Beagle dog.

Authors:  K Sharun; R Kumar; V Chandra; A C Saxena; A M Pawde; P Kinjavdekar; K Dhama; G T Sharma
Journal:  Iran J Vet Res       Date:  2021       Impact factor: 1.376

6.  Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.

Authors:  Junran Xie; Dongju Xiao; Yun Xu; Jinning Zhao; Li Jiang; Xuming Hu; Yaping Zhang; Lina Yu
Journal:  Oncotarget       Date:  2016-02-09

Review 7.  Veterinary Regenerative Medicine for Musculoskeletal Disorders: Can Mesenchymal Stem/Stromal Cells and Their Secretome Be the New Frontier?

Authors:  Michela Mocchi; Silvia Dotti; Maurizio Del Bue; Riccardo Villa; Elia Bari; Sara Perteghella; Maria Luisa Torre; Stefano Grolli
Journal:  Cells       Date:  2020-06-11       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.